Medullary thyroid carcinoma (MTC) is a malignant tumor that originates from the calcitonin producing and secreting C-cells in the thyroid gland (Horn, 1951) . MTC is the most important clinical manifestation of the multiple endocrine neoplasia type 2 (MEN 2) syndrome (Sipple et al., 1961) . MEN 2 is a familial cancer syndrome, inherited as a monogenic autosomal dominant trait (Steiner et al., 1968) . Apart from MTC, this syndrome is characterized by the occurrence of tumors originating from the chroman cells of the adrenal medulla (pheochromocytoma). In addition to these tumors, parathyroid hyperplasia is observed in MEN 2A (Sipple et al., 1961; Steiner et al., 1968) while in MEN 2B ganglioneuromas of the intestinal tract and mucosal neuromas are found, as well as musculoskeletal anomalies (Carney et al., 1976) . Mortality in MEN 2 patients is mainly caused by MTC metastases.
MEN 2 is associated with germline mutations in the RET proto-oncogene leading to aminoacid substitutions in its encoded transmembrane receptor tyrosine kinase. The RET receptor tyrosine kinase (Takahashi et al., 1988) serves as the receptor for the GDNF family of neurotrophic factors (Trupp et al., 1996) . RET is an essential component of signaling pathways required for renal organogenesis and enteric neurogenesis (Schuchardt et al., 1994) . Three RET isoforms that dier by 9, 43 and 51 aminoacids in the carboxyterminal domain are encoded due to alternative splicing of the pre-mRNA (Tahira et al., 1990; Myers et al., 1996) . In MEN 2A the mutations aect cysteine residues in the extracellular domain of the protein, which results in constitutive kinase activity (Mulligan et al., 1993; Donis-Keller et al., 1993) . Mutations associated with MEN 2A cause aberrant dimerization of RET via the formation of disulfate bonded homodimers (Asai et al., 1995; Santoro et al., 1995) . In MEN 2B the most common mutation results in a Met?Thr substitution at codon 918 in the intracellular domain of the protein. This mutation is also found as a somatic mutation in a high percentage (30 ± 40%) of sporadic MTC cases (Hofstra et al., 1994; Eng et al., 1994; Carlson et al., 1994) . The MEN 2B mutation appears to modify the substrate speci®city of the tyrosine kinase (Santoro et al., 1995) . All MEN2 mutations convert the RET proto-oncogene into a dominantly acting transforming gene in humans as expression of the non-mutated allele is usually retained in tumor tissue (Landsvater et al., 1996) , although somatic MEN 2B mutations have been described in tumors from MEN 2A patients (Marsh et al., 1996) .
To study biological eects of the MEN 2B mutation in the RET gene on the thyroid C-cells, we applied transgenic mouse technology to generate mice with Ccell-speci®c expression of a human RET transgene with the MEN2B-speci®c 918 Met?Thr mutation. As a control we generated mice with a non-mutated human RET transgene.
A transgene construct was made with a human RET oncogene cDNA encoding the RET9 isoform in which the MEN 2B-speci®c codon 918 Met?Thr substitution was introduced by site directed mutagenesis. A 1.5 kb human calcitonin gene (CALC-I) promoter fragment was used to direct its expression to the thyroid gland C-cells and an SV40 polyA signal and intron were introduced to obtain good expression of the transgene: CALC-MEN2B-RET. As a control a similar transgene construct, but with a non-mutated (wild type) human RET proto-oncogene, was generated: CALC-WT-RET. This enabled discrimination between eects caused by the point mutation and eects caused by the CALC promoter driven expression. Transgenic mice were generated by injection of pro-nuclei from fertilized oocytes from (C57BL6xDBA2) F1 mice and eight founder mice were obtained for each of the two constructs. From these founders, ®ve CALC-MEN2B-RET (Table 1) and four CALC-WT-RET transgenic lines were established by backcrossing to the C57BL6 strain. The numbers of (transgenic) ospring from each founder is indicated in Table 1 . The fact that not all founders established a transgenic line was either due to low reproduction capacity or lack of germline transmission. To test whether the transgene was expressed we isolated RNA from several organs from mice from all transgenic lines established and applied RT ± PCR using human RET-speci®c primers. The transgene-speci®c transcript was detected in the thyroid glands in all transgenic lines obtained. In addition, transgene expression was observed in brain, lung and kidney. This method did not allow a quantitative comparison of the expression level between the dierent transgenic lines. The presence of the MEN2B-speci®c point mutation in transgenic mRNA was detected by diagnostic restriction enzyme digestion with FokI (Hofstra et al., 1994) and was con®rmed by direct sequencing of the RT ± PCR products obtained.
Mice from all transgenic lines showed normal growth and reproduction and no gross abnormalities became apparent during the ®rst 10 months. We therefore sacri®ced two transgenic mice and two nontransgenic littermates from each line at the age of 4, 8 and 12 months for histological analyses of the thyroid gland. The thyroid gland was examined by systematically making microscopic slides from the whole thyroid gland and performing immuno-histochemistry for calcitonin to identify the C-cells. In humans, diuse C-cell hyperplasia (CCH) is characterized by both an increase in the numbers of C-cells per follicle and by an increase in the number of follicles with C-cells and strict criteria have been postulated . In mice, however the anatomical distribution of C-cells in the thyroid gland did not allow a clear distinction of diuse CCH from normal distribution, as also in nontransgenic mice the C-cells were often clustered in high numbers around individual follicles. A clear distinction however could be made between normal (diuse) distribution and nodular CCH. Figure 1a shows calcitonin immuno-histochemistry on the thyroid gland from an 8-month-old mouse from the CALC-MEN2B-RET transgenic line-06. The right hand lobe of the thyroid gland from this mouse shows normal diuse distribution of calcitonin positive C-cells. In the left lobe, besides diuse distribution, a nodule of C-cells was observed (arrow). In this lobe a parathyroid gland (P), not staining for calcitonin, was visible. At larger magni®cation (Figure 1b) , abnormal accumulation of C-cells and growth into the follicle lumen, leading to disruption of normal follicular architecture, were observed. These ®ndings are hallmarks for nodular CCH. The nodule of C-cells comprised an area with a crosssectional size of +0.6 mm.
At the age of 20 months a transgenic CALC-MEN2B-RET founder became ill and was sacri®ced. In this mouse large bilateral thyroid tumors had developed. The tumors had sizes of 12 and 7 mm in diameter. Histopathology of these tumors revealed areas of large rounded epithelial cells, divided by ®brous septa. Tumor cells showed nuclear pleiomorphism and frequent mitosis indicative for malignancy. Amyloid deposits with necrotic cell remnants and cyst formation and capsularization of the tumor were observed (Figure 1c ). In addition to the large tumors, multiple microscopic foci of MTC were observed in the normal thyroid tissue. Figure 1d shows calcitonin immuno-histochemistry on normal parafollicular Ccells (arrow) and micro-MTC's (M). The ®elds of tumor cells stained positive for calcitonin, unambiguously demonstrating that these were MTC's. Heterogeneity in calcitonin staining of tumor cells was observed in the micro-MTC's as well as in the large tumors in this mouse (Figure 1d,e) , a feature that is also seen in human MTC. Analyses of the other CALC-MEN2B-RET founders at this age revealed two more founders with large bilateral MTC. In Figure 1f the tumors from the founder of CALC-MEN2B-RET line-42 are shown, presenting with extensive capsular formation and vascularization with associated hemorrhage, in addition to the MTC-features described above. In two other CALC-MEN2B-RET founders nodular CCH was observed while three CALC-MEN2B-RET founders did not show clear thyroid abnormalities. Additional pathological lesions in these mice included lung carcinoma and lymphoma. None of the four CALC-WT-RET founders analysed at this age presented with thyroid gland abnormalities. In addition, autopsy of 27 mice from established CALC-WT-RET transgenic lines and 15 non-transgenic littermates, sacri®ced at an age of 18 ± 26 months, never revealed MTC. In these mice lymphomas were frequently found. In mice from CALC-WT-RET transgenic lines with high levels of aberrant RET expression in the kidney, development of renal cystic disease was observed. Also three CALC-WT-RET founders died from renal disease Increased basal plasma concentrations of calcitonin are a biochemical indication for MTC. We therefore measured basal calcitonin levels in plasma from the transgenic founders and three control non-transgenic age-matched mice using a chemi-luminiscence immunoassay (Nichols Institute Diagnostics). The detection limit of the assay was 1 ng/l. Of the four CALC-WT-RET founders or the three non-transgenic mice none had a detectable level of calcitonin. The three tumorbearing mice had a tremendous increase in plasma calcitonin concentration (1140 ± 3900 ng/l). The mice with nodular CCH had a low but detectable basal plasma calcitonin level of 3 ng/l and also in two founders in which no clear nodular CCH was found by histology a detectable plasma calcitonin level of 2 ng/l was observed. In one CALC-MEN2B-RET founder plasma calcitonin could not be detected (Table 1) . Since the measurement of basal plasma calcitonin levels may give an indication for the presence of MTC or nodular or diuse CCH, we monitored the CALC-MEN2B-RET transgenic mice and a group of nontransgenic littermates from 9 ± 24 months of age by this method. In the majority of non-transgenic littermates (86%) plasma calcitonin could not be detected. However, ®ve out of 37 (14%) presented with basal Deparanized sections were stained with hematoxylin and eosin (c, f) or used for immuno-histochemistry (a,b,d,e) . After blocking endogenous peroxidase (PO) with 1.5% H 2 O 2 , a rabbit polyclonal anti-calcitonin antibody (DAKO) at 1 : 8000 dilution was applied at room temperature (RT) for 1 h. The second and third PO-coupled antisera (DAKO) were both used at 1 : 50 dilutions for 30 min at RT. Di-amino-benzidine tetra-hydrochloride (DAB, Sigma) was used as substrate for PO activity. Slides were counterstained with Mayer's hematoxylin, dehydrated and mounted with Pertex. Samples without the use of primary antibody served as negative controls plasma calcitonin levels of 1 ± 2 ng/l, which may be a re¯ection of diuse CCH also observed with histological analysis in some non-transgenic mice. Similar percentages were found for three CALC-MEN2B-RET transgenic lines of which the founder had not developed MTC. In CALC-MEN2B-RET line-06 a signi®cantly larger percentage of mice (33%, P50.05) presented with detectable basal plasma calcitonin levels. In 77% of the mice from CALC-MEN2B-RET line-42 a plasma level of 1 ± 7 ng/l could be detected, while only three mice presented with undetectable levels (Figure 2) . In this line-42, in addition to the founder, a MTC was diagnosed in two other mice out of a total of 23 (13%). One presented with a plasma calcitonin level of 29 ng/l at the age of 17 months, while the other had a plasma calcitonin level of 770 ng/ l at the age of 11 months. These data indicate that in CALC-MEN2B-RET line-42 there is predisposition for CCH and subsequent progression to development of MTC.
For establishment of primary cell cultures from the CALC-MEN2B-RET-induced murine MTC a piece of tumor tissue (+26262 mm) from a CALC-MEN2B-RET line-42 transgenic mouse was removed aseptically and cut with two scalpel blades into small fragments. After washing with PBS, the tumor tissue was cultured in DMEM supplemented with 10% FCS in two 25 cm 2 asks. After 48 h non-adherent cells and tissue clumps were removed and fresh medium was added. Inspection of the cultures revealed ®broblasts and epithelial cells growing as colonies. After 4 weeks, approximately 50% con¯uency was reached. To determine whether these tumor cells produce and secrete calcitonin, the culture medium was conditioned during a 2 weeks culture period and calcitonin concentration was determined. Whereas in non-conditioned culture medium a calcitonin concentration of 3 ng/l was measured, the media conditioned for 2 weeks had calcitonin levels of 1000 and 550 ng/l, indicating that the tumor cells were still highly dierentiated and retained the capacity to produce and secrete calcitonin in culture. Upon further passage, however, the growth rate of the epithelial cells decreased. The cultures could be maintained for 3 ± 4 months.
Using transgenic mouse technology we generated a murine model for MTC. The CALC-MEN2B-RET transgene induced MTC in three of eight founders. From one of these a transgenic line-42 with predisposition for MTC development was established. One transgenic line-06 presented with a signi®cantly increased number of mice with nodular or diuse CCH. Thyroid abnormalities were never observed in non-transgenic mice or in CALC-WT-RET transgenic mice, expressing a non mutated RET proto-oncogene, thus demonstrating the oncogenic potential of the MEN 2B mutation for MTC induction in mice. The fact that not all CALC-MEN2B-RET transgenic lines show predisposition for MTC development may be explained by a dierence in expression level of the transgene in the thyroid gland Ccells. Development of a MEN 2B phenotype has previously been postulated to be sensitive to gene dosage. Both for transgenic mice in which a MEN2B-RET transgene was expressed in the developing sympathetic and enteric nervous system (Sweetser et al., 1999) and more recently, for a MEN 2B RET mouse strain generated by homologous recombination (Smith-Hicks et al., 2000) . In this latter mouse strain MTC has not yet been observed. In contrast to these mice, the CALC-MEN2B-RET mice harbor a multicopy transgene under the control of a heterologous promoter, which may account for the dierence in development of MTC. Also in transgenic mice with C-cell expression of a MEN2A-RET transgene variability in penetrance of the MTCphenotype between transgenic lines was observed (Michiels et al., 1997) . In addition to the results obtained with the MEN 2A transgenic mice, involvement of MEN 2A mutations in MTC-induction in mice has been demonstrated in RB+/7 and P53+/7 double mutant mice. In MTC from these mice somatic MEN2A RET mutations were detected. The MEN2B RET mutation, however, was not found (Coxon et al., 1998) . The data presented here are the ®rst demonstrating the involvement of the MEN2B RET mutation in MTC development in mice.
In human MEN 2 patients development of MTC is believed to proceed in several steps. Diuse C-cell hyperplasia is regarded as a preneoplastic state from which, upon acquirement of additional oncogenic hits and further progression, ®rst hyperplastic nodular foci and ®nally multicentric and bilateral MTC's develop. A similar phenotypical sequence is observed in the CALC-MEN2B-RET transgenic mice. The tumors that ®nally developed in these mice were morphologically similar to human MTC. The tumor cells produced and secreted calcitonin, which resulted in highly elevated basal plasma calcitonin levels. High levels of calcitonin production and secretion were maintained when the tumor cells were grown in culture.
The incomplete penetrance and the variable latency period for MTC development in the CALC-MEN2B-RET transgenic mice suggest that there is a requirement for additional oncogenic events. Analyses of the MEN2B RET-induced MTC may provide clues for the identi®cation of these additional hits. By crossing the Figure 2 Percentage of mice with C-cell hyperplasia detected by basal plasma calcitonin concentration. Basal plasma calcitonin concentration was determined in 200 ml plasma samples from mice from each indicated CALC-MEN2B-RET line and control non-transgenic littermates, using a chemi-luminescence immunoassay (Nichols Institute Diagnostics). Detection limit of the assay was 1 ng/l. The percentage of mice with a detectable basal plasma calcitonin level (bars) and the total number of mice for each group (n) are indicated. Comparison between each group of transgenic mice and the control group was done with the student's t-test. Signi®cant dierences are indicated *P50.05 and ***P50.001 CALC-MEN2B-RET mice with mice harboring mutated tumor suppressor genes or activated oncogenes implicated in MTC development or progression we can further address this issue.
In addition, the CALC-MEN2B-RET mice constitute a useful model for the evaluation of new diagnostic methods and to test novel forms of therapy, as no curative therapy is currently available for MTC.
